Elevated serum visfatin levels in patients with acute myocardial infarction

Archives of Iranian Medicine

Volumn 15, Issue 11, 2012, Pages 688-692

  Mazaherioun, Maryam ^a,b   Hosseinzadeh Attar, Mohammad Javad ^a,b   Janani, Leila ^a   Farahani, Ali Vasheghani ^c   Rezvan, Neda ^a   Karbaschian, Zohreh ^a   Hossein Nezhad, Arash ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Cytokines; Proinflammatory

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ROC CURVE; WAIST CIRCUMFERENCE;

EID: 84868241177     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wang Q, Rao S, Shen GQ, Li L, Moliterno DJ. Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identi-fied by genomewide linkage analysis. Am J Hum Genet. 2004; 74: 262-271.
2. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract. 2003; 134: 18-27.
3. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin EndocrinolMetab. 2004; 89(6): 2548-2556.
4. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: mo-lecular links between obesity and atherosclerosis. Am J Physiol Heart CircPhysiol. 2005; 288(5): 2031-2041.
5. Cheng KH, Chu CS, Lee KT, Lin TH, Hsieh CC, Chiu CC, et al. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes(Lond). 2008; 32(2): 268-274.
6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishi-moto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307 (5708): 426-430.
7. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell col-ony-enhancing factor. Mol Cell Biol. 1994; 14(2): 1431-1437.
8. McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, Ma SF, et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet. 2005; 43: 127-141.
9. Saddi-Rosa P, Oliveira SV, Giuffrida F, Reis A. Visfatin, glucose me-tabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010; 26(2): 21.
10. Mirzaei K, Hossein-Nezhad A, Hosseinzadeh-Attar M. J, Jafari N, Najmafshar A, Mohammadzadeh N, et al. Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes pa-tients. Minerva Endocrinol. 2009; 34(4): 273-279.
11. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007; 115(8): 972-980.
12. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007; 357(1): 150-156.
13. Romacho T, Azcutia V, Vbzquez-Bella M, Matesanz N, Cercas E, Ne-vado J, et al. Extracellular PBEF/NAMPT/visfatin activates pro-in-flammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009; 52(11): 2455-2463.
14. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syn-dromes (ACS) in humans. Clin Endocrinol. 2009; 71(2): 202-207.
15. Fu H, Zhu Y, You GY, Liu XJ. Detection of visfatin level of plasma in patients with coronary artery diseases. Sichuan da xue xue bao. Yi xue ban, Journal of Sichuan University. Medical Science Edition. 2009; 40(2): 322-324.
16. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab. 2006; 91(3): 1181-1184.
17. Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, Chiu CA, et al. Elevated Visfatin/Pre-B-cell Colony-enhancing Factor Plasma Concentration in Ischemic Stroke. J Stroke CerebrovascDis. 2009; 18(5): 354-359.
18. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gy-necol. 2002; 187: 1051-1058.
19. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond). 2008; 115(1): 13-23.
20. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65(9): 1198-1201.
21. Adya R, Tan BK, Chen J, Randeva HS. Nuclear Factor-kappaB In-duction by Visfatin in Human Vascular Endothelial Cells: Role in MMP-2/9 Production and Activation. Diabetes Care. 2008; 31(4): 758-760.
22. Pouliot MC, Desprqs JP, Lemieux S, Moorjani S, Bouchard C, Trem-blay A, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tis-sue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994; 73(7): 460-468.
23. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chi-nese population. Diabet Med. 2006; 23(9): 967-973.
24. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA ex-pression in humans. Diabetes. 2005; 54(10): 2911-2916.
25. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Re-duced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91(8): 3165-3170.
26. Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk H, et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertention. 2007; 21(2):173-175.
27. De Luis DA, Sagrado MG, Aller R, Conde R, Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines:A contradictory piece of the puzzle. Nutrition. 2010; 26(11): 1130-1133.